Gary Willers, DO
Family Medicine · Cuero, TXNPI 1255625422
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.4% of the total across 140 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 8.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $480 and has fallen 61.8% since, to $183 in 2025.
Across 140 payments — averaging $17.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$200
- Teva Pharmaceuticals USA, Inc.$196
- Merck$162
- Novartis$158
- Boehringer Ingelheim$151
- Astellas Pharma US Inc$147
- plus $1K from 31 others
What the payments were for
- Food & beverage$2,37295%
- Education$1155%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 21 | $200 |
| Teva Pharmaceuticals USA, Inc. | 9 | $196 |
| Merck | 9 | $162 |
| Novartis | 9 | $158 |
| Boehringer Ingelheim | 9 | $151 |
| Astellas Pharma US Inc | 4 | $147 |
| Otsuka America Pharmaceutical, Inc. | 10 | $146 |
| Lilly USA, LLC | 8 | $129 |
| Bayer | 7 | $123 |
| Johnson & Johnson | 3 | $122 |
| Novo Nordisk | 6 | $104 |
| Stryker | 1 | $73 |
| Intuitive Surgical | 1 | $63 |
| Pfizer | 5 | $63 |
| Amgen | 3 | $58 |
| Sanofi-aventis U.S. LLC | 4 | $54 |
| Tactile Systems Technology Inc | 3 | $51 |
| GSK | 2 | $45 |
| Xeris Pharmaceuticals, Inc. | 2 | $43 |
| Sun Pharmaceutical Industries Inc. | 2 | $41 |
| Solventum Corporation | 2 | $41 |
| Ardelyx, Inc. | 2 | $35 |
| Exact Sciences | 2 | $34 |
| Chiesi USA, Inc. | 2 | $32 |
| AstraZeneca | 2 | $28 |
| Amarin Pharma, Inc. | 1 | $23 |
| AMAG Pharmaceuticals, Inc. | 1 | $23 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $19 |
| Organon | 1 | $19 |
| Shield Therapeutics Inc | 1 | $17 |
| Averitas Pharma Inc. | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Mylan Specialty L.p. | 1 | $14 |
| Genentech USA, Inc. | 1 | $12 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $12 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $12 |
| Kerecis Limited | 1 | $9 |
How this compares
$2,487 in reported general payments places this provider in the 75th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 555 | $187,444 |
| MounjaroTirzepatide | 173 | $171,186 |
| OzempicSemaglutide | 161 | $166,011 |
| XtandiEnzalutamide | 19 | $132,777 |
| JardianceEmpagliflozin | 135 | $91,595 |
| MyrbetriqMirabegron | 204 | $67,551 |
| XareltoRivaroxaban | 167 | $61,724 |
| TrulicityDulaglutide | 64 | $61,536 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 81 | $60,443 |
| PulmozymeDornase Alfa | 13 | $52,333 |
| RybelsusSemaglutide | 17 | $41,252 |
| Breo ElliptaFluticasone/Vilanterol | 63 | $34,588 |
| FarxigaDapagliflozin Propanediol | 44 | $29,868 |
| RexultiBrexpiprazole | 18 | $24,031 |
| ProliaDenosumab | 12 | $20,120 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $129 | $232,722237 claims |
| Novo NordiskOzempic, Rybelsus | $104 | $207,263178 claims |
| Astellas Pharma US IncXtandi, Myrbetriq | $147 | $200,328223 claims |
| PfizerEliquis | $63 | $187,444555 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat, Synjardy | $151 | $119,576192 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $45 | $95,031144 claims |
| Johnson & JohnsonXarelto | $122 | $61,724167 claims |
| Genentech USA, Inc.Pulmozyme | $12 | $52,33313 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta | $28 | $43,19582 claims |
| MerckJanuvia, Janumet, Belsomra | $162 | $35,46570 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $146 | $24,03118 claims |
| AmgenProlia | $58 | $20,12012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Cuero
- Carlos CamposNew Braunfels$1.5M
- Aaron KingSan Antonio$1.1M
- Bradley WassonArlington$734K
- Cynthia BrinsonAustin$402K
- Michael MendezLubbock$368K
- Sang Tae KimAmarillo$368K
- Sumit PerakathuHarlingen$342K
- Joel SolisMcAllen$324K
- Robert CampbellFort Worth$318K
- Jose LedezmaEdinburg$300K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.